RxDoctor Payments Data

Denis Ostrovskiy, MD

Neurology · Lake Success, NYNPI 1437199668

Payments from drug & device makers

$301,385in general payments, 2019–2025

Across 1,542 payments — averaging $195.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$102K
  • Argenx US, Inc.$79K
  • MDD US Operations, LLC$43K
  • Amgen$33K
  • UCB, Inc.$27K
  • AbbVie$4K
  • plus $15K from 53 others

What the payments were for

  • Consulting fees$18,4698%
  • Speaking & faculty fees$165,12372%
  • Travel & lodging$17,1277%
  • Food & beverage$30,17613%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)158$101,558
Argenx US, Inc.124$78,587
MDD US Operations, LLC220$42,659
Amgen(2 entities)91$33,256
UCB, Inc.55$26,632
AbbVie(2 entities)164$3,688
Johnson & Johnson3$2,340
Pfizer117$1,825
Novartis160$1,724
SK Life Science, Inc.53$868
Biohaven Pharmaceuticals, Inc.15$582
Biogen36$537
Grifols USA, LLC22$537
EMD Serono, Inc.28$530
Scilex Pharmaceuticals Inc.25$463
Takeda Pharmaceuticals U.S.A., Inc.16$429
Biohaven Pharmaceutical Holding Company Ltd.23$377
Teva Pharmaceuticals USA, Inc.13$346
Acadia Pharmaceuticals Inc17$340
Sanofi18$337
Eisai Inc.10$312
Lundbeck LLC23$287
Acorda Therapeutics, Inc21$223
Avanir Pharmaceuticals, Inc.9$207
CSL Behring4$195
Neurocrine Biosciences, Inc.8$187
Amylyx Pharmaceuticals, Inc.5$179
Bristol Myers Squibb10$159
Lilly USA, LLC9$157
Kyowa Kirin, Inc.6$153
Sunovion Pharmaceuticals Inc.9$148
Amneal Pharmaceuticals LLC7$141
E.r. Squibb & Sons, L.L.C.2$136
Catalyst Pharmaceuticals, Inc.7$130
Medtronic3$117
Tanabe Pharma America, Inc.5$105
GE HealthCare4$82
Ipsen Biopharmaceuticals, Inc3$70
Otsuka America Pharmaceutical, Inc.3$62
Mallinckrodt Hospital Products Inc.2$62
Octapharma USA, Inc.3$59
Vertex2$58
Upsher-smith Laboratories LLC3$54
Vertical Pharmaceuticals, LLC3$51
Supernus Pharmaceuticals, Inc.3$49
Abbott1$46
Impel Pharmaceuticals Inc.2$43
Neurelis, Inc.1$42
Banner Life Sciences, LLC2$39
Mallinckrodt Enterprises LLC2$35
Vanda Pharmaceuticals Inc.2$32
Akcea Therapeutics, Inc.2$28
Boston Scientific1$28
Assertio Therapeutics, Inc.2$24
Alnylam Pharmaceuticals Inc.1$17
Strongbridge US Inc.1$15
Genentech USA, Inc.1$13
Promius Pharma LLC1$12
Livanova USA, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$301,385 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$534,767
Medicare patients
1,310
Services billed
2,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab26$1,224,808
PanzygaImmun Glob G(Igg)-Ifas/Glycine26$649,393
Radicava OrsEdaravone24$352,194
Gamunex-CImmune Globul G/Gly/Iga Avg 4629$318,246
GammakedImmune Globul G/Gly/Iga Avg 4611$218,946
NuplazidPimavanserin Tartrate25$217,326
NeuproRotigotine21$18,984
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone24$11,033
Rasagiline Mesylate72$9,111
Tegretol XrCarbamazepine38$7,943
Mycophenolate Mofetil59$7,684
Carbidopa-LevodopaCarbidopa/Levodopa219$6,595
Pramipexole ErPramipexole Di-Hcl15$6,381
Entacapone24$5,614
Oxcarbazepine47$5,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$78,587$1,224,80826 claims
PfizerPanzyga$1,825$649,39326 claims
Grifols USA, LLCGamunex-C$537$318,24629 claims
Acadia Pharmaceuticals IncNuplazid$340$217,32625 claims
UCB, Inc.Neupro$26,632$18,98421 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$141$9,75383 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Lake Success

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →